SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs steep slide to new lows is drawing bearish discussion, with traders linking the selloff to concerns about Trumps political standing and the approaching midterms, as well as the companys weak business fundamentals. Some see the decline as a possible trading opportunity, but negative sentiment dominates.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep slide to post-IPO lows dominates discussion, with traders citing newly unlocked shares and insider selling, TD Cowens price-target cut, and concerns about valuation, growth and customer concentration amid weakness in AI-related stocks. Bearish calls for more downside contrast with buyers arguing the shares are oversold and adding on dips.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff has focused attention on its debt load, borrowing costs and ability to finance its AI infrastructure expansion amid broader doubts about neocloud economics. Traders are split between bargain-buying and short-squeeze hopes and concern about further downside or dilution; a Goldman Sachs upgrade failed to sustain a rebound.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing attention amid a broad semiconductor selloff and concerns about whether AI infrastructure spending can generate sustainable returns; traders also blame CEO Hock Tans remarks likening some AI investing to gambling for adding to uncertainty. Bulls view the pullback as a buying opportunity based on custom-chip demand, while bears worry about AI financing risks and the stocks persistent underperformance.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp rally is drawing attention after Morgan Stanley named it a top pick, citing stronger expected AWS growth and its AI opportunity. Many traders welcomed the upgrade and saw room for further gains, while others questioned whether the move would hold ahead of earnings and watched for resistance.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

A sharp selloff in CleanSpark shares, amid weakness across bitcoin miners and concerns about debt costs, management and the AI/data-center pivot, is driving discussion. Traders are split between expecting further declines and buying what they see as an oversold dip, with some long-term holders citing the Meta-backed data-center plans as a counterpoint.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock, citing long commercialization timelines, limited firm customer commitments and projected cash burn. Traders are debating whether the selloff reflects real execution risks or an overly bearish analyst call, with some buying the dip on the long-term nuclear-power thesis.

AGNC Investment Corp. engages in the operation of a real estate investment trust. The firm invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It also invests in other types of mortgage and mortgage-related securities, such as credit risk transfer securities and non-Agency residential and commercial mortgage-backed securities, where repayment of principal and interest is not guaranteed by the United States government-sponsored enterprise or by the United States Government agency, and other assets related to the housing, mortgage, or real estate markets. The company was founded on January 7, 2008 and is headquartered in Bethesda, MD.

AGNC Investment Corp

AGNCs Q3 results have put its sharp tangible book value decline and weak economic return at the center of discussion; spread income only narrowly covered the dividend. Traders are split between concerns about further losses and a potential dividend cut, and buyers treating the selloff as an opportunity to add income shares.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs prolonged steep selloff, including its underperformance while Bitcoin has held relatively firm, dominates discussion. Traders blame weak sentiment around the companys AI/data-center pivot and lack of signed tenant leases, alongside short-selling and management concerns; some see a possible bounce, but bearish frustration is widespread.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on AbCelleras ABCL635 Phase 2 data for menopausal hot flashes, with traders focused on whether conference updates add evidence on durability, safety and patient outcomes beyond the encouraging topline results. Bullish traders see the data as validation of the companys pipeline, while others caution that expectations may be high and the presentation could offer little new information or prompt profit-taking.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?

Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400PR NewswireBOULDER, Colo., Oct. 8, 2026 Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at...

Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?

Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireBOULDER, Colo., Oct. 1, 2026BOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc...

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500PR NewswireBOULDER, Colo., Sept. 22, 2026 - TheMoA that...

Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? 

Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire BOULDER, Colo., Sept. 2, 2026 BOULDER, Colo., Sept. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc...

Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?

BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.

Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026

Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 PR Newswire BOULDER, Colo...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Edgewise Therapeutics Inc

EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The acquisition includes Edgewise’s muscular dystrophy operations and its lead drug candidate, Sevasemten.</li><li>Sevasemten is currently being evaluated in a pivotal trial for Becker muscular dystrophy and a Phase 2 study for Duchenne muscular dystrophy.</li><li>The transaction is expected to close in the third quarter of 2026.</li></ul>Shares of Edgewise Therapeutics (EWTX) soared more than 20% on Monday, climbing to record high, after French drugmaker Servier unveiled a multibillion-dollar deal to acquire the company’s muscular dystrophy business.<a href="https://stocktwits.com/symbol/EWTX">EWTX shares</a> could clock their biggest single-day gains in more than six months if the stock closes at current levels.<h2 class="st-heading-2">EWTX To Receive $1.55B Upfront</h2>On Monday, Servier expanded its footprint in rare neuromuscular disorders through a $2.65 billion deal to acquire Edgewise Therapeutics’ muscular dystrophy business, including programs targeting Becker and Duchenne muscular dystrophies.Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and commercial milestones. The transaction is expected to close in the third quarter of 2026.<h2 class="st-heading-2">EWTX’s Sevasemten In Spotlight</h2>The acquisition includes Edgewise’s muscular dystrophy operations and its lead drug candidate, Sevasemten. The investigational oral therapy is designed to protect fragile muscles from contraction-related damage in patients with rare muscular dystrophies.Sevasemten is currently being evaluated in a pivotal trial for Becker muscular dystrophy (BMD) and a Phase 2 study for Duchenne muscular dystrophy (DMD). There are currently no approved treatments for BMD, a rare genetic disorder that causes progressive muscle weakness and loss of function.“This transaction is designed to place the program in the hands of an organization with the experience and infrastructure to support its continued development for people living with Becker and Duchenne muscular dystrophies,” said Kevin Koch, CEO of Edgewise Therapeutics.<h2 class="st-heading-2">Sevasemten Shows Strong Safety Profile</h2>Edgewise’s MESA extension study is currently evaluating the long-term safety and effectiveness of Sevasemten in patients with Becker muscular dystrophy.According to data presented at the 2026 MDA Clinical and Scientific Conference in March, patients maintained stable physical function for up to 3.5 years, compared with the decline typically seen in the disease. The drug also demonstrated a favorable cardiac safety profile over 12 months, with signs of improved cardiac function in some patients.<h2 class="st-heading-2">EWTX Sentiment Remains Bullish</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, amid ‘high’ message volumes.One user noted that upon completion of the deal, Edgewise will become a cardiovascular-focused company.<stembedurl>https://stocktwits.com/G101SPM/message/654951591</stembedurl>The stock has gained around 30% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-glsi-stock-rising-today-form-10k-delay-update-breast-cancer-trial/cZ0gpnyReH0">GLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and commercial milestones.

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$37.92
Prev Close	$37.19
Open	$37.41
Dividend Yield	0.00%
50-Day Moving Average	$42.18
Beta	1.46
Avg. Volume	1.64M
PE Ratio	-20.51

52-Week High	$48.51
52-Week Low	$14.68
Market Capitalization	$4.04B
EPS (Annual)	-$1.63
Price to Book	9.12
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

EWTX Fundamentals